Literature DB >> 10761460

Extramammary Paget disease is characterized by the consistent lack of estrogen and progesterone receptors but frequently expresses androgen receptor.

E Diaz de Leon1, M L Carcangiu, V G Prieto, P A McCue, J L Burchette, G To, B A Norris, A J Kovatich, R L Sanchez, H R Krigman, Z Gatalica.   

Abstract

Extramammary Paget disease (EPD) is an uncommon cutaneous malignant neoplasm that arises in areas rich in apocrine glands (perineum, vulva, and axilla). Apocrine gland origin or apocrine differentiation of cells of EPD has been suggested. Estrongen, progesterone, and androgen hormone receptors have been reported to exhibit a characteristic pattern of expression in mammary apocrine type carcinomas; however, their expression in EPD has not been elucidated fully. By using immunohistochemical methods, we studied the expression of steroid receptors in EPD on formalin-fixed paraffin-embedded tissue samples from 28 patients with EPD without associated visceral malignant neoplasms or adnexal carcinoma. Androgen receptor (AR) was identified in 15 of 28 cases. The proportion of AR-positive cells varied from 1% to more than 75%; 8 cases expressed AR in more than 10% of cells. Strong AR expression also was seen in the invasive carcinoma arising from 1 case of EPD. All cases lacked immunohistochemically detectable estrogen and progesterone receptors. The immunophenotype characteristic of apocrine carcinomas (AR-positive, estrogen receptor-negative, progesterone receptor-negative) was seen in a substantial proportion of EPD cases. Results suggest that AR expression is a factor in pathogenesis of EPD. This may be important for the therapy of recurrent or invasive disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761460     DOI: 10.1309/P756-XXCB-TV71-U4XV

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  10 in total

Review 1.  Skin adnexal neoplasms--part 2: an approach to tumours of cutaneous sweat glands.

Authors:  Nidal A Obaidat; Khaled O Alsaad; Danny Ghazarian
Journal:  J Clin Pathol       Date:  2006-08-01       Impact factor: 3.411

Review 2.  A primer on extramammary Paget's disease for the urologist.

Authors:  Joon Yau Leong; Paul H Chung
Journal:  Transl Androl Urol       Date:  2020-02

Review 3.  [Extramammary Paget's disease].

Authors:  I Cosgarea; A Zaremba; U Hillen
Journal:  Hautarzt       Date:  2019-09       Impact factor: 0.751

4.  Management of penoscrotal extramammary Paget disease: case series and review of the literature.

Authors:  P Moretto; V J Nair; S El Hallani; S Malone; E Belanger; C Morash; C M Canil
Journal:  Curr Oncol       Date:  2013-08       Impact factor: 3.677

5.  Detection and genomic characterization of a mammary-like adenocarcinoma.

Authors:  Jasleen K Grewal; Peter Eirew; Martin Jones; Kenrry Chiu; Basile Tessier-Cloutier; Anthony N Karnezis; Aly Karsan; Andy Mungall; Chen Zhou; Stephen Yip; Anna V Tinker; Janessa Laskin; Marco Marra; Steven J M Jones
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-11-21

6.  GATA3 is a sensitive marker for primary genital extramammary paget disease: an immunohistochemical study of 72 cases with comparison to gross cystic disease fluid protein 15.

Authors:  Ming Zhao; Lixin Zhou; Li Sun; Yan Song; Yunquan Guo; Xun Zhang; Feng Zhao; Peng Wang; Junqiu Yue; Dongfeng Niu; Zhongwu Li; Xiaozheng Huang; Qiang Kang; Lin Jia; Jinping Lai; Dengfeng Cao
Journal:  Diagn Pathol       Date:  2017-07-10       Impact factor: 2.644

7.  Mammary and Extramammary Paget's Disease Presented Different Expression Pattern of Steroid Hormone Receptors.

Authors:  Songxia Zhou; Weixiang Zhong; Ruiqin Mai; Guohong Zhang
Journal:  Biomed Res Int       Date:  2017-09-10       Impact factor: 3.411

Review 8.  Metastatic Extramammary Paget's Disease: Pathogenesis and Novel Therapeutic Approach.

Authors:  Keitaro Fukuda; Takeru Funakoshi
Journal:  Front Oncol       Date:  2018-02-16       Impact factor: 6.244

9.  Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.

Authors:  Zoran Gatalica; Semir Vranic; Božo Krušlin; Kelsey Poorman; Phillip Stafford; Denisa Kacerovska; Wijendra Senarathne; Elena Florento; Elma Contreras; Alexandra Leary; April Choi; Gino K In
Journal:  Cancer Med       Date:  2020-01-03       Impact factor: 4.452

10.  Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin.

Authors:  Emma Zattarin; Federico Nichetti; Francesca Ligorio; Laura Mazzeo; Riccardo Lobefaro; Giovanni Fucà; Giorgia Peverelli; Andrea Vingiani; Giulia V Bianchi; Giuseppe Capri; Filippo de Braud; Claudio Vernieri
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.